Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Strikes $500m Deal For GSK Cephalosporins

Deal To Acquire Cephalosporins Business Reinforces Position In Antibiotics

Executive Summary

Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.

You may also be interested in...



Sandoz CEO Takes Stock Of Generics Industry After A Year Of Lockdowns

Sandoz CEO Richard Saynor has spoken of the ways in which the pandemic has changed the industry, from supply chains to working patterns, and makes predictions for the years ahead.

Deal Watch: BMS Looks To Molecular Templates’ Engineered Toxin Bodies In Cancer

Plus recent deals involving AbbVie/Caribou, Sanofi/i2O, Merck & Co./Starpharma, Protalix/SarcoMed, Targovax/Papyrus, Medivir/Ubiquigent, Eton/Azurity

Sandoz Strikes €150m Deal On Antibiotics In Austria

Sandoz has announced joint plans with the Austrian government to invest over €150m in antibiotics manufacturing.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150660

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel